Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Alamos Gold -- Ignore unavailable to you. Want to Upgrade?

To: Miner who wrote (2791)	6/16/2002 10:21:17 PM
From: Al Collard	Respond to of 4470

Hi John, Your in with DMX-t @$ 3.46 for 5,780 shares. Chart for Dimethaid Research, Inc: stockcharts.com[h,a]dacaniay[dc][pc20!b50!f][vc60][iLa12,26,9!Ll14]&pref=G From the chart of DMX we can see the stock broke down under it's 20EMA last week on average volume. The chart indicators are bearish and without news the stock appears to be headed to test 52 week lows. Good luck with this pick, Al Not sure where Chucka is. I know he was on holidays last week and was experiencing internet problems before he left.

To: Miner who wrote (2791)	6/17/2002 8:37:38 AM
From: Al Collard	Read Replies (1) \| Respond to of 4470

DMX-t...in the news: Globes says Dimethaid kills U.K. ointment deal Mon 17 Jun 2002 The Globe and Mail reports in its Saturday, June 15, edition that Dimethaid Research of Markham, Ont., says it has ended a British sales and marketing deal with Provalis Healthcare for distribution of Pennsaid, an ointment to treat arthritis. The Globe's Briefing column reports that Dimethaid in January, 2001, awarded the Provalis PLC unit exclusive rights to market and distribute the drug in Britain, where seven million people suffer from osteoarthritis. Provalis was expected to meet minimum sales targets by March. "We fully expected Pennsaid to be achieving greater sales and market penetration in the United Kingdom than has been the case to date," Dimethaid said in a release. Dimethaid stock slipped four cents to finish Friday at $3.46, sixteen cents ahead of its 52-week low, on the Toronto Stock Exchange Friday. The stock has a 52-week high of $6.85.